Results 21 to 30 of about 908,413 (222)

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Hepatology, EarlyView., 2022
Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann, Marti Cabanes‐Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien‐Huber, Ahmed Abdelrahman, Xuan‐Khang Vu, Liang Zhang, Ann‐Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez‐Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwäble, Leszek Lisowski, Hildegard Büning   +25 more
wiley   +1 more source

Literature review and clinical observation of acquired idiopathic hemophilia with a new missense mutation in the factor VIII gene (His2026Arg) [PDF]

Терапевтический архив, 2018
The article provides review of possible mechanisms of inhibitor coagulopathies, in particular of acquired hemophilia A. This pathology is an extremely rare disease occurring in 1-2 cases in 1 million per year. In the present study we provide data for two
V I ERSHOV, I Yu GADAEV, D A BUDANOVA, F G PERINA, V L SURIN, V V SALOMASHKINA, O S PSHENICHNIKOVA, N I ZOZULYA   +7 more
doaj   +1 more source

The problem of acquired hemophilia [PDF]

Blood, 2015
In this issue of Blood , Andreas Tiede et al report the results of a German, Austrian, and Swiss registry (GTH-AH study) of acquired hemophilia and identify prognostic factors that may guide the choice of immunosuppressive treatment (IST) to eradicate the autoantibody contributing to the outcome ...
Francesco Baudo, Francesco de Cataldo
openaire   +2 more sources

Immunoadsorption for the Treatment of Acquired Hemophilia: New Observational Data, Systematic Review, and Meta-Analysis. [PDF]

, 2021
The treatment of patients with acquired hemophilia is challenging due to life-threatening hemorrhages, delayed response, and adverse effects to immunosuppressive agents. Even though immunoadsorption (IA) rapidly removes autoantibodies against factor VIII,
Daskalakis, Michael, Mueller, Martin, Kremer Hovinga, Johanna Anna, Esteves Pereira, Michael, Bocksrucker, Christoph, Nagler, Michael, Mansouri Taleghani, Behrouz, Martin Mueller, Michael Esteves Pereira, Michael Nagler, Christoph Bocksrucker, Johanna Anna Kremer Hovinga, Michael Daskalakis, Behrouz Mansouri Taleghani   +13 more
core   +2 more sources

Laboratory work-up of acquired hemophilia A [PDF]

, 2022
The paper presents the major aspects of laboratory diagnosis of acquired hemophilia A (AHA). The author discusses the difficulties encountered in the process of detecting this coagulopathy.
Odnoczko, Edyta; Department of Hemostasis and Metabolic Disorders Institute of Hematology and Transfusion Medicine in Warsaw, Edyta Odnoczko   +1 more
core   +1 more source

Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]

, 2000
Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N., Gesierich, Wolfgang, Pohlmann, H., Munker, Reinhold, Geiersberger, U., Hartenstein, R.   +5 more
core   +1 more source

Acquired hemophilia A (AHA): underreported, underdiagnosed, undertreated medical condition

The Egyptian Journal of Internal Medicine, 2022
Background Acquired hemophilia A (AHA) is a rare acquired bleeding disorder occurred due to the formation of inhibitory antibodies neutralizing endogenous factor VIII. Main body About half the cases are idiopathic.
Doaa M. El Demerdash, Alia Ayad, Noha Tawfik   +2 more
doaj   +1 more source

Postpartum-acquired hemophilia: A challenging disease to manage

Journal of Applied Hematology, 2017
Acquired hemophilia is a severe bleeding diathesis that affects both males and females. It is caused by suddenly appearing autoantibodies that interfere with the coagulation factor VIII activity.
Mohammed A Karish, Amr Hanbali, Hazzaa Al Zahrani, Rahaf Al Sahli   +3 more
doaj   +1 more source

Acquired factor VIII deficiency in prostate adenocarcinoma presenting as multiple hematomas and hemarthrosis

SAGE Open Medical Case Reports, 2020
Acquired hemophilia A or acquired factor VIII deficiency is a rare bleeding disorder due to the presence of autoantibodies to factor VIII. It has been associated with autoimmune conditions, certain medications, and malignancy. It has a high morbidity and
Akeem Lewis, Joe Joseph, Nirmal Pathak, Babak Baseri, Carol Luhrs   +4 more
doaj   +1 more source

Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia

, 2009
Anti-factor VIII (FVIII) inhibitory IgG may arise as alloantibodies to therapeutic FVIII in patients with congenital hemophilia A, or as autoantibodies to endogenous FVIII in individuals with acquired hemophilia.
Srinivas V. Kaveri, Uda, Taizo, Bayry, Jagadeesh, Borg, Jeanne-Yvonne, Jordan D. Dimitrov, Rao, Desirazu N., Sébastien Lacroix-Desmazes, Borel-Derlon, Annie, Jeanne-Yvonne Borg, Friboulet, Alain, Taizo Uda, Jagadeesh Bayry, Mahendra, Ankit, Dimitrov, Jordan D., Desirazu N. Rao, Kaveri, Srinivas V., Wootla, Bharath, Lacroix-Desmazes, Sébastien, Bharath Wootla, Annie Borel-Derlon, Ankit Mahendra, Alain Friboulet   +21 more
core   +2 more sources